Tamoxifen (ICI) and Tamoxifen (Ebewe) have identical efficacy in treating metastasizing breast carcinoma, with no observed severe side effects.

Wiener medizinische Wochenschrift

Results of adjuvant hormone therapy with Tamoxifen, an antioestrogenic substance, have been discussed. 82 patients in 2 groups who were diagnosed with metastatic mammary carcinoma received Tamoxifen (ICI) and Tamoxifen (Ebewe) orally in a dosage of 20 to 40 mg/day. 43% of the patients in group A (Tamoxifen, ICI) experienced complete or partial remission of the metastases. In group B (Tamoxifen, Ebewe), this result was achieved in 54% of cases. The better results were due to the fact that the disease was not so advanced in the group B patients and they were also longer in the menopause. Thus in terms of efficacy, the preparations are identical. Severe side effects due to the therapy were not observed.

Tamoxifen (ICI) and Tamoxifen (Ebewe) have identical efficacy in treating metastasizing breast carcinoma, with no observed severe side effects.

[The treatment of metastasizing breast carcinoma using antiestrogens].